ME LICENSE #: TF284

CERTIFICATE OF ANALYSIS

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

LOT-387-QC0003 (EDIBLE SOLID) // PRODUCED: MAR 01, 2024

CLIENT: CANNEUTICS, LLC // BATCH: PASS



MATRIX: EDIBLE SOLID 1
DENSITY: 0.9586 g/ml 2
SAMPLE ID: NAL-240227-028
COLLECTED ON: FEB 27, 2024
RECEIVED ON: FEB 27, 2024
SAMPLE SIZE: 2.01 G 1

SAMPLED BY: KEVIN P MCALOON RECEIVED BY: DYLAN ARRIGO SERVING SIZE: .3 ML ¹ PACKAGE SIZE: .3 ML ¹

1 ENTERED BY CLIENT, 2 ENTERED BY LAB

| CANNABINOID OVERVIEW | |
|----------------------|--------------|
| CBG: | 12.0 mg/srv |
| CBC: | 0.569 mg/srv |
| TOTAL CANNABINOIDS: | 12.9 mg/srv |
| | |

CULTIVATOR INFO

CULTIVATOR
KEVIN MCALOON
LICENSE

CGR26593 MEDICINAL - CAREGIVER

MANUFACTURER INFO

MANUFACTURER KEVIN MCALOON

LICENSE CGR26593

MEDICINAL - CAREGIVER

BATCH RESULT: PASS

| POTENCY | TESTED |
|----------|--------|
| TERPENES | TESTED |

CAN.1: POTENCY & CANNABINOID PROFILE BY HPLC-UV PREPARATION: FEB 28, 2024 // ANALYSIS: FEB 29, 2024

| ANALYTE | LIMIT AMT | AMT | LOD/LOQ (mg/ml) | PASS/FAIL | ANALYTE | LIMIT AMT | AMT | LOD/LOQ (mg/ml) | PASS/FAIL |
|----------------------|-----------|-------------|-----------------|-----------|-------------------------|-------------|-----------|-----------------|-----------|
| СВС | 0.198 % | 1.90 mg/ml | 0.0625/0.125 | N/A | Δ ¹⁰ -ΤΗC | ND | ND | 0.0625/0.125 | N/A |
| CBCA | ND | ND | 0.0625/0.125 | N/A | EXO-THC | ND | ND | 0.125/0.125 | N/A |
| CBD | 0.0601 % | 0.576 mg/ml | 0.0625/0.125 | N/A | THCA | ND | ND | 0.125/0.125 | N/A |
| CBDA | ND | ND | 0.0625/0.125 | N/A | THCV | ND | ND | 0.0625/0.125 | N/A |
| CBDV | ND | ND | 0.0625/0.125 | N/A | THCVA | ND | ND | 0.0625/0.125 | N/A |
| CBDVA | ND | ND | 0.0625/0.125 | N/A | TOTAL THC** | 0.0302 % 0. | 289 mg/ml | | N/A |
| CBG | 4.19 % | 40.2 mg/ml | 0.0625/0.125 | N/A | TOTAL CBD** | 0.0601 % 0. | 576 mg/ml | | N/A |
| CBGA | ND | ND | 0.0625/0.125 | N/A | CBD/SRV | 0.173 mg | _ | | N/A |
| CBL | ND | ND | 0.125/0.125 | N/A | Δ ⁹ -THC/SRV | 0.0868 mg | | | N/A |
| CBLA | ND | ND | 0.0625/0.125 | N/A | TOTAL THC/SRV** | 0.0868 mg | | | N/A |
| CBN | ND | ND | 0.0625/0.125 | N/A | TOTAL CBD/SRV** | 0.173 mg | | | N/A |
| CBNA | ND | ND | 0.0625/0.125 | N/A | CBD/PKG | 0.173 mg | | | N/A |
| Δ8-THC | ND | ND | 0.125/0.125 | N/A | Δ ⁹ -THC/PKG | 0.0868 mg | | | N/A |
| Δ ⁸ -THCA | ND | ND | 0.125/0.125 | N/A | TOTAL THC/PKG** | 0.0868 mg | | | N/A |
| Δ ⁹ -ΤΗC | 0.0302 % | 0.289 mg/ml | 0.0625/0.125 | N/A | TOTAL CBD/PKG** | 0.173 mg | | | N/A |

** TOTAL CBD = (CBDA X 0.877) + CBD

** TOTAL THC = (THCA X 0.877) + THC

Reported on an as received basis

 $1000 \mu g/g = 1 mg/g$



AUTHORIZED BY: ZACHARY SMITH LABORATORY MANAGER, NOVA ANALYTIC LABS MAR 01, 2024



| ANALYTE | AMT | AMT I | LOD/LOQ (mg/ml) P/ | ASS/FAIL | ANALYTE | AMT | AMT | LOD/LOQ (mg/ml) | PASS/FAIL |
|------------------------|---------------|---------|--------------------|----------|-------------------|-----|-----|-----------------|-----------|
| TOTAL TERPENES | 0.146 % 1.4 | 0 mg/ml | | N/A | FARNESOL | ND | ND | 0.136/0.273 | N/A |
| α-BISABOLOL | 0.0641 % 0.61 | 4 mg/ml | 0.136/0.273 | N/A | FENCHONE | ND | ND | 0.136/0.273 | N/A |
| GUAIOL | 0.0486 %0.46 | 6 mg/ml | 0.136/0.273 | N/A | y-TERPINENE | ND | ND | 0.136/0.273 | N/A |
| β-CARYOPHYLLENE | 0.0331 %0.31 | 7 mg/ml | 0.136/0.273 | N/A | GERANIOL | ND | ND | 0.136/0.273 | N/A |
| α-HUMULENE | < LOQ | < LOQ | 0.136/0.273 | N/A | GERANYL ACETATE | ND | ND | 0.136/0.273 | N/A |
| (-)-VERBENONE | ND | ND | 0.136/0.273 | N/A | ISOBORNEOL | ND | ND | 0.136/0.273 | N/A |
| 2-PIPERIDONE | ND | ND | 0.136/0.273 | N/A | ISOBORNYL ACETATE | ND | ND | 0.136/0.273 | N/A |
| α-CEDRENE | ND | ND | 0.136/0.273 | N/A | ISOPULEGOL | ND | ND | 0.136/0.273 | N/A |
| α-PHELLANDRENE | ND | ND | 0.136/0.273 | N/A | LINALOOL | ND | ND | 0.136/0.273 | N/A |
| α-PINENE | ND | ND | 0.136/0.273 | N/A | M - C Y M E N E | ND | ND | 0.136/0.273 | N/A |
| α-TERPINENE | ND | ND | 0.136/0.273 | N/A | MENTHOL | ND | ND | 0.136/0.273 | N/A |
| α-THUJONE | ND | ND | 0.136/0.273 | N/A | MENTHONE | ND | ND | 0.136/0.273 | N/A |
| β-MYRCENE | ND | ND | 0.136/0.273 | N/A | NEROL | ND | ND | 0.136/0.273 | N/A |
| β-PINENE | ND | ND | 0.136/0.273 | N/A | O-CYMENE | ND | ND | 0.136/0.273 | N/A |
| BORNEOL | ND | ND | 0.136/0.273 | N/A | OCTYL ACETATE | ND | ND | 0.136/0.273 | N/A |
| CAMPHENE | ND | ND | 0.136/0.273 | N/A | P-CYMENE | ND | ND | 0.136/0.273 | N/A |
| CAMPHOR | ND | ND | 0.136/0.273 | N/A | PHYTANE | ND | ND | 0.136/0.273 | N/A |
| CARVACROL | ND | ND | 0.136/0.273 | N/A | PIPERITONE | ND | ND | 0.136/0.273 | N/A |
| CARYOPHYLLENE OXIDE | ND | ND | 0.136/0.273 | N/A | PULEGONE | ND | ND | 0.136/0.273 | N/A |
| CEDROL | ND | ND | 0.136/0.273 | N/A | SABINENE | ND | ND | 0.136/0.273 | N/A |
| CIS-β-OCIMENE | ND | ND | 0.136/0.273 | N/A | SABINENE HYDRATE | ND | ND | 0.136/0.273 | N/A |
| CITRAL | ND | ND | 0.136/0.273 | N/A | SAFRANAL | ND | ND | 0.136/0.273 | N/A |
| CITRONELLOL | N D | ND | 0.136/0.273 | N/A | TERPINEN-4-OL | ND | ND | 0.136/0.273 | N/A |
| D-CARVONE | ND | ND | 0.136/0.273 | N/A | TERPINEOL | ND | ND | 0.136/0.273 | N/A |
| D-LIMONENE | ND | ND | 0.136/0.273 | N/A | TERPINOLENE | ND | ND | 0.136/0.273 | N/A |
| Δ ³ -CARENE | ND | ND | 0.136/0.273 | N/A | THYMOL | ND | ND | 0.136/0.273 | N/A |
| E-NEROLIDOL | ND | ND | 0.136/0.273 | N/A | TRANS-β-OCIMENE | ND | ND | 0.136/0.273 | N/A |
| ENDO FENCHYL ALCOHO | L ND | ND | 0.136/0.273 | N/A | VALENCENE | ND | ND | 0.136/0.273 | N/A |
| EUCALYPTOL | ND | ND | 0.136/0.273 | N/A | Z-NEROLIDOL | ND | ND | 0.136/0.273 | N/A |
| FARNESENE | ND | ND | 0.136/0.273 | N/A | | | | | |

NOTES

ZACHARY SMITH

POTENCY & CANNABINOID PROFILE BY HPLC-UV

MAR 01, 2024 THE STANDARD LAB UNCERTAINTY FOR POTENCY IS 5% OF THE REPORTED VALUE.

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

ALL TESTS WERE PERFORMED IN ACCORDANCE WITH THE RULES AND REGULATIONS SET FORTH IN THE MAINE ADULT USE PROGRAM. LABORATORY SAMPLING PROTOCOLS ARE GOVERNED BY THE OCP'S SAMPLING GUIDANCE DOCUMENTS. ALL INFORMATION PROVIDED BY THE CLIENT, INCLUDING SELF SAMPLING, MUST BE ACCURATE AND ADHERE TO THE SAME RULES AND REGULATIONS. HOWEVER, CLIENT PROVIDED INFORMATION, INCLUDING SAMPLING, IS ULTIMATELY THE RESPONSIBILITY OF THE PROVIDING LICENSEE, REGISTERED CAREGIVER, PATIENT OR THE LIKE AND FAILURE TO FOLLOW SAID PROTOCOLS COULD LEAD TO ERROPEOUS TEST RESULTS. NOT ALL POTENTIAL AND/OR EXISTING HAZARDS WERE ANALYZED, THIS CERTIFICATE OF ANALYSIS IS RELEVANT ONLY TO THOSE ITEMS TESTED. THE SAMPLE WAS PROVIDED TO THE LABORATORY FOR TESTING BY THE CLIENT AND THE SAMPLE WAS TESTED AS RECEIVED.

END OF REPORT

